General MedicationsORALGeneric
VITEKTA
ELVITEGRAVIR
Standard Dose
150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview VITEKTA is listed in Drugs@FDA under application 203093 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ELVITEGRAVIR Form and strength TABLET;ORAL - 150MG Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2016-01-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview VITEKTA is listed in Drugs@FDA under application 203093 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ELVITEGRAVIR Form and strength TABLET;ORAL - 150MG Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2016-01-21 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.